United States · Amendment · SAMDT
SAMDT 2111 (112th)
To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market.
Introduced
—
Last action
—
Status
Amendment SA 2111, under the order of 5/23/12, not having achieved 60 votes in the affirmative, was not agreed to in Senate by Yea-Nay Vote. 28 - 67. Record Vote Number: 105.
Sponsors
—
Subjects
Discovery layer
Source updated
25 February 2022
Records
Official amendment SAMDT 2111 (112th) from United States at United States Congress. Status: Amendment SA 2111, under the order of 5/23/12, not having achieved 60 votes in the affirmative, was not agreed to in Senate by Yea-Nay Vote. 28 - 67. Record Vote Number: 105..
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/amendment/112th-congress/samdt-2111
- Open data entity: https://api.congress.gov/v3/amendment/112/samdt/2111